Navigation Links
Tetanus toxin found to have therapeutic properties

A team of researchers from the Department of Biochemistry and Molecular Biology and the Institute of Neuroscience at the Universitat Autònoma de Barcelona has discovered that tetanus toxin, which causes tetanus, could be extremely useful as a therapy against psychological disorders such as depression, anxiety and anorexia, and to slow the progress of neurodegenerative disorders such as Parkinson's disease.

Tetanus toxin is a neurotoxin belonging to the same family as botulinum neurotoxins, which cause botulism. These have been successfully used as a therapy to treat disorders caused by abnormal muscular contractions such as strabismus, cerebral palsy, anal contractions and torticollis. Recently these toxins have been used even in cosmetics against wrinkles. For these therapeutic and cosmetic applications, the scientists are working with sublethal doses of toxins.

Led by José Aguilera, scientists from the Department of Biochemistry and Molecular Biology and the Institute of Neuroscience at the UAB, have studied whether it would also be possible to use sublethal doses of tetanus toxin and molecules derived from tetanus toxin for therapeutic purposes. The results have been obtained in the laboratory after 20 years of studying these toxins, and they are very encouraging.

Two separate, distinct parts form the tetanus toxin molecule: one part is the cause of the toxic effects and the tetanus symptoms; the other, however, is harmless and is able to penetrate and affect the nervous system. This harmless part, called the carboxy-terminal domain, has been reproduced in large quantities in the laboratory so that tests can be carried out on its effects on the nervous system of rats.

The experiments have shown that the harmless part inhibits serotonin from being transported through the synaptic membranes, i.e. the membranes that connect the neurones so that signals can be sent through the brain. The molecule is as effective as the selective inhibit ors currently used, but they are more powerful, they last longer, and they are more specific. This inhibitory effect converts the molecule into what could be a drug with many uses. It would be more effective than Prozac and more effective than any drug that works by selectively inhibiting the transportation of serotonin in the nerve endings. Behavioural disorders such as depression, anxiety and anorexia may be treated using the molecule derived from tetanus toxin.

The researchers have also been able to show that toxin and its recombinant fragment, carboxy terminal, the harmless fragment, strengthens the neural cells and protects them from external aggressions. This means it has a neuroprotective effect that prevents the death of the neurons when they are faced with aggressive situations. This is why the scientists believe the harmless toxin fragment could be more effective than neurotrophins as protection against neurodegenerative disorders such as Parkinson's disease.


Source:Universitat Autonoma de Barcelona

Related biology news :

1. Defensins neutralize anthrax toxin
2. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
3. Structures of marine toxins provide insight into their effectiveness as cancer drugs
4. Prenatal exposure to marine toxin causes lasting damage
5. UCSD study finds anthrax toxins also harmful to fruit flies
6. Scientists design potent anthrax toxin inhibitor
7. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
8. Scientists reveal how deadly toxin hijacks cells
9. Scientists develop a way to make the deadliest toxin known even more toxic
10. Yale researchers find environmental toxins disruptive to hearing in mammals
11. Evolution mystery: Spider venom and bacteria share same toxin
Post Your Comments:

(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... 2015  Champions Oncology, Inc. (CSBR), engaged in the ... the development and use of oncology drugs, today announced ... be presenting at the LD MICRO Investor Conference on ... (PST).  The conference, held at the Luxe Sunset Bel ... , will feature 200 small/micro-cap companies and is expected ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
Breaking Biology Technology: